642 - mRNA-1608, an mRNA-Based Therapeutic Genital Herpes Vaccine Candidate: Interim Safety, Immunogenicity and Clinical Endpoint Results from a Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Trial

Presenting Author(s)

• AW

  Anna Wald, MD, MPH

  Professor
  University of Washington
  Seattle, WA, United States

  Slides

Co-Author(s)

• CC

  Christy A. Comeaux, MD, PhD

  Senior Director
  Moderna Inc
  Cambridge, Massachusetts, United States
• AE

  Alan Embry, PhD

  Moderna Therapeutics
  Cambridge, Massachusetts, United States
• 

  Kenneth H. Mayer, MD (he/him/his)

  Medical Research Director
  Fenway Health
  Boston, MA, United States
• RR

  Rekha R. Rapaka, MD, PhD

  Clinical Director, Infectious Diseases
  Moderna Therapeutics
  Cambridge, Massachusetts, United States
• LG

  Lei Gao, PhD

  Moderna Inc
  Cambridge, Massachusetts, United States
• ZL

  Zhantao Lin, PhD

  Moderna Inc
  Cambridge, Massachusetts, United States
• PB

  Philip Buck, PhD, MPH

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• SC

  Sumana Chandramouli, PhD

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• JR

  Jamie Rosen, n/a

  Moderna Inc
  Cambridge, Massachusetts, United States
• JW

  Jessica Winer, n/a

  Moderna Inc
  Cambridge, Massachusetts, United States
• AD

  Adrienne Dunn, n/a

  Moderna Inc
  Cambridge, Massachusetts, United States
• HW

  Haixing Wang, PhD

  Associate Directory
  Moderna Inc
  Cambridge, Massachusetts, United States
• AF

  Alec Freyn, PhD

  Moderna Inc
  Cambridge, Massachusetts, United States
• RP

  Robert Paris, MD

  Moderna, Inc.
  Cambridge, Massachusetts, United States